Treating multiple myeloma resistant to BCMA-targeted therapy

Independent symposium at the 10th World Congress on Controversies in Multiple Myeloma (COMy)Подробнее

What should myeloma patients know about talquetamab?Подробнее

How might IVIG therapy be used to treat infection after BCMA-targeted therapies in MM?Подробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Update in Multiple MyelomaПодробнее

A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig HofmeisterПодробнее

Updates on AL Amyloidosis Treatment: What is New in 2023 | Dana-Farber Cancer InstituteПодробнее

Sequencing BCMA Myeloma TherapiesПодробнее

What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?Подробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

Using BCMA-targeting agents in earlier lines of treatment for multiple myelomaПодробнее

Relapsed Refractory Multiple Myeloma | Current Treatment Options | Options on the HorizonПодробнее

Treatment options for patients with multiple myeloma who are resistant to daratumumabПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

CAR T-cells in Multiple MyelomaПодробнее

Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MDПодробнее

Immunotherapy 101 for Multiple Myeloma PatientsПодробнее

BCMA Therapy & the Road to Remission in MyelomaПодробнее

What are dual CAR-T cells? #myelomaПодробнее

Moving BCMA-targeted agents to the frontline setting in myeloma & sequencing immunotherapiesПодробнее